These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24775917)

  • 1. Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor.
    Yu DD; Lin W; Forman BM; Chen T
    Bioorg Med Chem; 2014 Jun; 22(11):2919-38. PubMed ID: 24775917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists.
    Huang H; Yu Y; Gao Z; Zhang Y; Li C; Xu X; Jin H; Yan W; Ma R; Zhu J; Shen X; Jiang H; Chen L; Li J
    J Med Chem; 2012 Aug; 55(16):7037-53. PubMed ID: 22862148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, and Biological Evaluation of Novel Nonsteroidal Farnesoid X Receptor (FXR) Antagonists: Molecular Basis of FXR Antagonism.
    Huang H; Si P; Wang L; Xu Y; Xu X; Zhu J; Jiang H; Li W; Chen L; Li J
    ChemMedChem; 2015 Jul; 10(7):1184-99. PubMed ID: 25982493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural optimization and in vitro profiling of N-phenylbenzamide-based farnesoid X receptor antagonists.
    Schmidt J; Schierle S; Gellrich L; Kaiser A; Merk D
    Bioorg Med Chem; 2018 Aug; 26(14):4240-4253. PubMed ID: 30026040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound.
    Lamers C; Merk D; Gabler M; Flesch D; Kaiser A; Schubert-Zsilavecz M
    Future Med Chem; 2016; 8(2):133-48. PubMed ID: 26824277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
    Yu DD; Lin W; Chen T; Forman BM
    Bioorg Med Chem; 2013 Jul; 21(14):4266-78. PubMed ID: 23688559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of potent farnesoid X receptor (FXR) antagonist showing favorable PK profile and distribution toward target tissues: Comprehensive understanding of structure-activity relationship of FXR antagonists.
    Teno N; Yamashita Y; Masuda A; Iguchi Y; Oda K; Fujimori K; Hiramoto T; Nishimaki-Mogami T; Une M; Gohda K
    Bioorg Med Chem; 2019 Jun; 27(11):2220-2227. PubMed ID: 31029550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel pyrazole-3-carboxamide derivatives as cannabinoid-1 (CB1) antagonists: journey from non-polar to polar amides.
    Sasmal PK; Reddy DS; Talwar R; Venkatesham B; Balasubrahmanyam D; Kannan M; Srinivas P; Kyasa SK; Devi BN; Jadhav VP; Khan SK; Mohan P; Chaudhury H; Bhuniya D; Iqbal J; Chakrabarti R
    Bioorg Med Chem Lett; 2011 Jan; 21(1):562-8. PubMed ID: 21075633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of novel SIPI-7623 derivatives as farnesoid X receptor (FXR) antagonists.
    Nian SY; Wang GP; Jiang ZL; Xiao Y; Huang MH; Zhou YH; Tan XD
    Mol Divers; 2019 Feb; 23(1):19-33. PubMed ID: 29974364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicinal chemistry and pharmacological effects of Farnesoid X Receptor (FXR) antagonists.
    Lamers C; Schubert-Zsilavecz M; Merk D
    Curr Top Med Chem; 2014; 14(19):2188-205. PubMed ID: 25388533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonacidic Chemotype Possessing
    Teno N; Yamashita Y; Iguchi Y; Fujimori K; Une M; Nishimaki-Mogami T; Hiramoto T; Gohda K
    ACS Med Chem Lett; 2018 Feb; 9(2):78-83. PubMed ID: 29456791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and SAR study of hydroxyacetophenone derivatives as potent, non-steroidal farnesoid X receptor (FXR) antagonists.
    Liu P; Xu X; Chen L; Ma L; Shen X; Hu L
    Bioorg Med Chem; 2014 Mar; 22(5):1596-607. PubMed ID: 24513188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators.
    Chae E; Shin YJ; Ryu EJ; Ji MK; Ryune Cho N; Lee KH; Jeong HJ; Kim SJ; Choi Y; Seok Oh K; Park CE; Soo Yoon Y
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2134-9. PubMed ID: 23434029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of N-(1H-pyrazol-4-yl)carboxamide inhibitors of interleukin-1 receptor associated kinase 4: Bicyclic core modifications.
    Lim J; Altman MD; Baker J; Brubaker JD; Chen H; Chen Y; Kleinschek MA; Li C; Liu D; Maclean JK; Mulrooney EF; Presland J; Rakhilina L; Smith GF; Yang R
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5384-8. PubMed ID: 26403930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of new non-steroidal farnesoid X receptor modulators through 3D shape similarity search and structure-based virtual screening.
    Wang L; Si P; Sheng Y; Chen Y; Wan P; Shen X; Tang Y; Chen L; Li W
    Chem Biol Drug Des; 2015 Apr; 85(4):481-7. PubMed ID: 25228339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and identification of a new farnesoid X receptor (FXR) partial agonist by computational structure-activity relationship analysis: Ligand-induced H8 helix fluctuation in the ligand-binding domain of FXR may lead to partial agonism.
    Gohda K; Iguchi Y; Masuda A; Fujimori K; Yamashita Y; Teno N
    Bioorg Med Chem Lett; 2021 Jun; 41():128026. PubMed ID: 33839252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.
    Kainuma M; Makishima M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2007 Apr; 15(7):2587-600. PubMed ID: 17292610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and SAR study of 3-(tert-butyl)-4-hydroxyphenyl benzoate and benzamide derivatives as novel farnesoid X receptor (FXR) antagonists.
    Song K; Xu X; Liu P; Chen L; Shen X; Liu J; Hu L
    Bioorg Med Chem; 2015 Oct; 23(19):6427-36. PubMed ID: 26337021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist.
    Hu L; Ren Q; Deng L; Zhou Z; Cai Z; Wang B; Li Z
    Eur J Med Chem; 2021 Feb; 211():113106. PubMed ID: 33360559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists.
    Marinozzi M; Carotti A; Sansone E; Macchiarulo A; Rosatelli E; Sardella R; Natalini B; Rizzo G; Adorini L; Passeri D; De Franco F; Pruzanski M; Pellicciari R
    Bioorg Med Chem; 2012 Jun; 20(11):3429-45. PubMed ID: 22564381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.